Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2

Human tumor heterogeneity promotes therapeutic failure by increasing the likelihood of resistant cell subpopulations. The PARP-1 inhibitor olaparib is approved for use in BRCA-mutated ovarian cancers but BRCA2-reversion mutations lead to functional homologous recombination repair (HRR) and olaparib...

Descripción completa

Detalles Bibliográficos
Autores principales: Rytelewski, Mateusz, Vareki, Saman Maleki, Mangala, Lingegowda S., Romanow, Larissa, Jiang, Dahai, Pradeep, Sunila, Rodriguez-Aguayo, Christian, Lopez-Berestein, Gabriel, Figueredo, Rene, Ferguson, Peter J., Vincent, Mark, Sood, Anil K., Koropatnick, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991495/
https://www.ncbi.nlm.nih.gov/pubmed/26959114
http://dx.doi.org/10.18632/oncotarget.7883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991495/
https://www.ncbi.nlm.nih.gov/pubmed/26959114
http://dx.doi.org/10.18632/oncotarget.7883

Ejemplares similares